{"id":"latanoprost-0-005-xalatan","safety":{"commonSideEffects":[{"rate":"10–15","effect":"Increased iris pigmentation (darkening)"},{"rate":"25–35","effect":"Conjunctival hyperemia (redness)"},{"rate":"5–10","effect":"Eyelash growth (hypertrichosis)"},{"rate":"5–10","effect":"Eye irritation or discomfort"},{"rate":"5–10","effect":"Periocular skin darkening"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Latanoprost binds to prostaglandin F receptors in the eye and enhances drainage of fluid through the uveoscleral (unconventional) pathway, which is the primary mechanism for lowering intraocular pressure. This reduction in IOP helps prevent or slow optic nerve damage and vision loss in glaucoma and ocular hypertension. The drug is administered as a topical ophthalmic solution.","oneSentence":"Latanoprost is a prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:43.762Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07325240","phase":"PHASE4","title":"24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-11-21","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":30},{"nctId":"NCT07354516","phase":"PHASE2, PHASE3","title":"Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"Qlaris Bio, Inc.","startDate":"2026-03-18","conditions":"OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension","enrollment":36},{"nctId":"NCT06819046","phase":"","title":"Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment","status":"COMPLETED","sponsor":"Colorado Ophthalmology Associates PC","startDate":"2025-02-14","conditions":"Glaucoma","enrollment":70},{"nctId":"NCT07465913","phase":"PHASE4","title":"Rocklatan vs Latanoprost Post-DSLT","status":"NOT_YET_RECRUITING","sponsor":"Eye Centers of Southeast Texas","startDate":"2026-05-06","conditions":"Glaucoma","enrollment":36},{"nctId":"NCT04412096","phase":"PHASE4","title":"Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2020-11-23","conditions":"Glaucoma, OHT - Ocular Hypertension","enrollment":59},{"nctId":"NCT07425535","phase":"EARLY_PHASE1","title":"Optic Nerve Head Strain in Non-glaucoma Subjects","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-03","conditions":"Glaucoma","enrollment":30},{"nctId":"NCT07082816","phase":"PHASE3","title":"Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alcon Research","startDate":"2025-09-02","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":489},{"nctId":"NCT07310719","phase":"NA","title":"A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital","status":"RECRUITING","sponsor":"Lagos State Health Service Commission","startDate":"2025-10-15","conditions":"Primary Open Angle Glaucoma or Ocular Hypertension","enrollment":138},{"nctId":"NCT06441643","phase":"PHASE2","title":"Next Generation Rocklatan","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-09-04","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":426},{"nctId":"NCT07209410","phase":"PHASE4","title":"Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma","status":"RECRUITING","sponsor":"Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,","startDate":"2025-11-01","conditions":"Glaucoma","enrollment":35},{"nctId":"NCT06449352","phase":"PHASE4","title":"Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost","status":"COMPLETED","sponsor":"Westlake Eye Specialists","startDate":"2024-06-13","conditions":"Normal Tension Glaucoma","enrollment":100},{"nctId":"NCT04500574","phase":"PHASE1","title":"Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension","status":"TERMINATED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2024-04-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":1},{"nctId":"NCT04630808","phase":"PHASE3","title":"MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2020-11-09","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":696},{"nctId":"NCT07048886","phase":"PHASE4","title":"Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)","status":"NOT_YET_RECRUITING","sponsor":"Center for Sight Las Vegas","startDate":"2025-07-15","conditions":"Primary Open Angle Glaucoma","enrollment":68},{"nctId":"NCT04445519","phase":"PHASE3","title":"Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2020-06-01","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":691},{"nctId":"NCT06964191","phase":"PHASE2","title":"Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"PolyActiva Pty Ltd","startDate":"2025-05-31","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":75},{"nctId":"NCT07016113","phase":"PHASE2","title":"0.005% Latanoprost Gel for Nonsegmental Vitiligo","status":"NOT_YET_RECRUITING","sponsor":"Universitas Padjadjaran","startDate":"2025-07-01","conditions":"Vitiligo - Macular Depigmentation","enrollment":10},{"nctId":"NCT06960629","phase":"","title":"The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)","status":"ENROLLING_BY_INVITATION","sponsor":"University Hospital Dubrava","startDate":"2025-04-01","conditions":"Pseudophakic Bullous Keratopathy, Glaucoma","enrollment":50},{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT05583474","phase":"PHASE3","title":"OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2022-09-27","conditions":"Open Angle Glaucoma or Ocular Hypertension","enrollment":204},{"nctId":"NCT06666855","phase":"PHASE3","title":"A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China","status":"RECRUITING","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2024-11-28","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":338},{"nctId":"NCT06407973","phase":"PHASE4","title":"A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma","status":"TERMINATED","sponsor":"Sight Sciences, Inc.","startDate":"2024-08-21","conditions":"Primary Open Angle Glaucoma","enrollment":2},{"nctId":"NCT06730516","phase":"EARLY_PHASE1","title":"Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2024-06-24","conditions":"Glaucoma","enrollment":56},{"nctId":"NCT06629129","phase":"PHASE1","title":"Effect of Latanoprost on Optic Nerve Perfusion","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2024-06-24","conditions":"Treatment Outcome","enrollment":46},{"nctId":"NCT01704989","phase":"PHASE4","title":"The Laser in Pseudoexfoliation (LIP) Study","status":"WITHDRAWN","sponsor":"Nova Scotia Health Authority","startDate":"2012-06","conditions":"Glaucoma","enrollment":""},{"nctId":"NCT02801617","phase":"PHASE3","title":"Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2015-09","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":116},{"nctId":"NCT04761705","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"SUSPENDED","sponsor":"JeniVision, Inc.","startDate":"2021-03-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":70},{"nctId":"NCT06239324","phase":"PHASE1, PHASE2","title":"Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser","status":"RECRUITING","sponsor":"Egymedicalpedia","startDate":"2024-02-01","conditions":"Alopecia Areata","enrollment":70},{"nctId":"NCT05283395","phase":"PHASE4","title":"Rocklatan® Evaluation","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2022-03-28","conditions":"Glaucoma","enrollment":136},{"nctId":"NCT02981446","phase":"PHASE3","title":"A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2017-01","conditions":"Open Angle Glaucoma or Ocular Hypertension","enrollment":370},{"nctId":"NCT04702789","phase":"PHASE4","title":"Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-10-19","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":28},{"nctId":"NCT05495061","phase":"PHASE3","title":"A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2022-08-09","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":325},{"nctId":"NCT04811326","phase":"PHASE4","title":"Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation","status":"UNKNOWN","sponsor":"Shaimaa Fawzy Abdel-rady Abdel-latif","startDate":"2021-01-13","conditions":"Non-segmental Vitiligo","enrollment":150},{"nctId":"NCT05513924","phase":"PHASE2, PHASE3","title":"Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.","status":"COMPLETED","sponsor":"South Valley University","startDate":"2022-03-15","conditions":"Vitiligo","enrollment":40},{"nctId":"NCT03657797","phase":"PHASE2","title":"Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2018-08-01","conditions":"Glaucoma, Open-Angle, Hypertension, Ocular","enrollment":656},{"nctId":"NCT05606796","phase":"PHASE4","title":"Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos.","status":"UNKNOWN","sponsor":"Uzoma Chinyei Joan","startDate":"2022-12","conditions":"Effect of Drug","enrollment":76},{"nctId":"NCT05165290","phase":"PHASE3","title":"Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure","status":"UNKNOWN","sponsor":"TearClear Corp","startDate":"2021-11-29","conditions":"Elevated Intraocular Pressure","enrollment":300},{"nctId":"NCT04296916","phase":"NA","title":"Effect of Lowering IOP in Glaucoma Suspects With HM","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-17","conditions":"Glaucoma, Suspect, High Myopia","enrollment":264},{"nctId":"NCT02585375","phase":"PHASE4","title":"Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2015-09-17","conditions":"Glaucoma, Ocular Hypertension","enrollment":70},{"nctId":"NCT03284853","phase":"PHASE3","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-09-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":436},{"nctId":"NCT03949244","phase":"PHASE4","title":"Nailfold Capillary Blood Flow With Latanoprost Bunod","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-08-15","conditions":"Glaucoma, Open-Angle","enrollment":47},{"nctId":"NCT00383019","phase":"PHASE3","title":"A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-11-14","conditions":"Glaucoma, Ocular Hypertension","enrollment":300},{"nctId":"NCT03648229","phase":"PHASE4","title":"African Glaucoma Laser Trial","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2019-09-01","conditions":"Open-angle Glaucoma","enrollment":""},{"nctId":"NCT04896125","phase":"","title":"Comparison of Different Drugs on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-10-02","conditions":"Glaucoma; Ocular Disorders (I.E. Caused by Ocular Disorders)","enrollment":300},{"nctId":"NCT00572455","phase":"PHASE2","title":"Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-12-11","conditions":"Primary Open-Angle Glaucoma, Ocular Hypertension","enrollment":318},{"nctId":"NCT00950690","phase":"","title":"Efficacy and Tolerability of Xalatan in Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":1289},{"nctId":"NCT00856622","phase":"PHASE3","title":"A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1997-08","conditions":"Ocular Hypertension, Glaucoma, Open-angle Glaucoma","enrollment":436},{"nctId":"NCT00800267","phase":"PHASE3","title":"A Study of Glaucoma or Ocular Hypertension in Patients Within the United States","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1997-07","conditions":"Ocular Hypertension, Glaucoma","enrollment":418},{"nctId":"NCT00230763","phase":"PHASE3","title":"Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-09","conditions":"Glaucoma, Primary Open Angle (POAG), Ocular Hypertension","enrollment":396},{"nctId":"NCT04737928","phase":"NA","title":"Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2018-04-02","conditions":"Glaucoma, Primary Open Angle","enrollment":1},{"nctId":"NCT00716859","phase":"PHASE3","title":"A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-07","conditions":"Glaucoma","enrollment":139},{"nctId":"NCT00638742","phase":"PHASE1","title":"A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT00847483","phase":"PHASE4","title":"Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2002-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":375},{"nctId":"NCT00647101","phase":"PHASE4","title":"A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-12","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":600},{"nctId":"NCT00846989","phase":"PHASE1, PHASE2","title":"Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":276},{"nctId":"NCT02466399","phase":"PHASE2","title":"POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma","status":"COMPLETED","sponsor":"Peregrine Ophthalmic","startDate":"2015-07","conditions":"Glaucoma","enrollment":80},{"nctId":"NCT03216902","phase":"PHASE2","title":"A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2017-07-25","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":241},{"nctId":"NCT00595101","phase":"PHASE2","title":"A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-12","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":117},{"nctId":"NCT00441883","phase":"PHASE2","title":"Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-03","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma","enrollment":176},{"nctId":"NCT04461249","phase":"","title":"Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2019-06-01","conditions":"Primary Open Angle Glaucoma","enrollment":60},{"nctId":"NCT04234932","phase":"EARLY_PHASE1","title":"Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation","status":"UNKNOWN","sponsor":"University of the Incarnate Word","startDate":"2020-01-06","conditions":"Glaucoma, Open-Angle","enrollment":10},{"nctId":"NCT02017327","phase":"PHASE4","title":"Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2013-12","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":379},{"nctId":"NCT03293992","phase":"PHASE1","title":"A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-10","conditions":"Glaucoma, Open-angle, Ocular Hypertension","enrollment":27},{"nctId":"NCT04178863","phase":"PHASE4","title":"CATS Tonometer IOP Reduction Latanoprost Verses Timolol","status":"UNKNOWN","sponsor":"Intuor Technologies, Inc.","startDate":"2018-07-01","conditions":"Glaucoma; Drugs","enrollment":72},{"nctId":"NCT01527682","phase":"PHASE2","title":"Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2009-07","conditions":"Childhood Glaucoma","enrollment":37},{"nctId":"NCT02558400","phase":"PHASE3","title":"Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2015-09-18","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":718},{"nctId":"NCT02057575","phase":"PHASE2","title":"Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2014-01","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":298},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT02674854","phase":"PHASE3","title":"Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2016-02","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":750},{"nctId":"NCT00440011","phase":"PHASE4","title":"Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-08","conditions":"Glaucoma, Ocular Hypertension","enrollment":266},{"nctId":"NCT00539526","phase":"PHASE4","title":"Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-09","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":106},{"nctId":"NCT00735449","phase":"PHASE4","title":"Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":204},{"nctId":"NCT01243567","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06-01","conditions":"Glaucoma, Open-Angle","enrollment":81},{"nctId":"NCT02419508","phase":"PHASE4","title":"SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-08-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":290},{"nctId":"NCT03611348","phase":"PHASE2, PHASE3","title":"Microneedling and Latanoprost in Acrofacial Vitiligo","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2018-09-01","conditions":"Vitiligo","enrollment":70},{"nctId":"NCT02059278","phase":"PHASE3","title":"Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nephron Pharmaceuticals Corporation","startDate":"2014-01","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":335},{"nctId":"NCT01223378","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-12-13","conditions":"Intraocular Pressure","enrollment":413},{"nctId":"NCT00712400","phase":"NA","title":"Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2005-06","conditions":"Ocular Physiology, Intraocular Pressure, Regional Blood Flow","enrollment":24},{"nctId":"NCT01927406","phase":"PHASE4","title":"The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2014-06","conditions":"Thyroid Eye Disease, Ocular Hypertension, Glaucoma","enrollment":""},{"nctId":"NCT02179008","phase":"PHASE2","title":"Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2014-06","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":184},{"nctId":"NCT01868126","phase":"PHASE2","title":"Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2013-05","conditions":"Open-angle Glaucoma or Ocular Hypertension","enrollment":91},{"nctId":"NCT01731002","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2012-11","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":224},{"nctId":"NCT02622334","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-12-29","conditions":"Glaucoma","enrollment":45},{"nctId":"NCT02129673","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"ViSci Ltd.","startDate":"2014-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":77},{"nctId":"NCT02829996","phase":"PHASE2","title":"Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG","status":"COMPLETED","sponsor":"Inotek Pharmaceuticals Corporation","startDate":"2016-08-19","conditions":"Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)","enrollment":201},{"nctId":"NCT02822742","phase":"PHASE3","title":"A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2016-07-02","conditions":"Primary Open Angle Glaucoma or Ocular Hypertension","enrollment":26},{"nctId":"NCT02623738","phase":"PHASE2, PHASE3","title":"A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2015-12-06","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":253},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT02278614","phase":"PHASE3","title":"Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2014-12","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":242},{"nctId":"NCT01315574","phase":"PHASE4","title":"Effects of Anti-Glaucoma Medications on the Ocular Surface","status":"TERMINATED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2011-02","conditions":"Glaucoma","enrollment":14},{"nctId":"NCT01254370","phase":"PHASE2","title":"Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2010-11","conditions":"Glaucoma, Ocular Hypertension, Ocular Surface Disease","enrollment":105},{"nctId":"NCT02083289","phase":"PHASE2","title":"A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2014-05","conditions":"Ocular Hypertension, Open Angle-glaucoma","enrollment":123},{"nctId":"NCT00705757","phase":"PHASE4","title":"The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye","status":"COMPLETED","sponsor":"Summa Health System","startDate":"2008-03","conditions":"Glaucoma, Application Site Pigmentation Changes","enrollment":89},{"nctId":"NCT02350023","phase":"PHASE4","title":"Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2014-09","conditions":"Alopecia Areata","enrollment":50},{"nctId":"NCT01975714","phase":"PHASE4","title":"Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study","status":"COMPLETED","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2013-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":67},{"nctId":"NCT00941525","phase":"PHASE4","title":"Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-09","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":174},{"nctId":"NCT01721707","phase":"PHASE3","title":"Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH","status":"WITHDRAWN","sponsor":"Adapt Produtos Oftalmológicos Ltda.","startDate":"2012-12","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT00706927","phase":"NA","title":"Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2006-01","conditions":"Retina, Ocular Physiology","enrollment":16},{"nctId":"NCT01369771","phase":"PHASE4","title":"The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma","status":"COMPLETED","sponsor":"FinnMedi Oy","startDate":"2010-08","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":30},{"nctId":"NCT01896180","phase":"PHASE2","title":"Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost","status":"COMPLETED","sponsor":"Alleanza Pharmaceuticals, Inc.","startDate":"2013-07","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension, Elevated Intraocular Pressure","enrollment":63}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":68,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"latanoprost 0.005% (Xalatan)","genericName":"latanoprost 0.005% (Xalatan)","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Latanoprost is a prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}